Specific and efficient gene delivery to the lung has been hampered by liver sequestration of adenovirus serotype 5 (Ad5) vectors. The complexity of Ad5 liver tropism has largely been unraveled, permitting improved efficacy of Ad5 gene delivery. However, Kupffer cell (KC) scavenging and elimination of Ad5 still represent major obstacles to lung gene delivery strategies. KC uptake substantially reduces bioavailability of Ad5 for target tissues and compensatory dose escalation leads to acute hepatotoxicity and a potent innate immune response. Here, we report a novel lung-targeting strategy through redirection of Ad5 binding to the concentrated leukocyte pool within the pulmonary microvasculature. We demonstrate that this leukocyte-binding approach retargets Ad5 specifically to lung endothelial cells and prevents KC uptake and hepatocyte transduction, resulting in 165 000-fold enhanced lung targeting, compared with Ad5. In addition, myeloid cell-specific binding is preserved in single-cell lung suspensions and only Ad.MBP-coated myeloid cells achieved efficient endothelial cell transduction ex vivo. These findings demonstrate that KC sequestration of Ad5 can be prevented through more efficient uptake of virions in target tissues and suggest that endothelial transduction is achieved by leukocyte-mediated 'hand-off' of Ad.
INTRODUCTION
Initial limitations to gene transfer technology, including safety concerns, 1 tempered much of the early enthusiasm for gene therapy. However, recent cures obtained with gene therapy have demonstrated both the safety and efficacy of virus-based gene delivery platforms and have piqued renewed interest in this technology. 2, 3 Nevertheless, the true potential of this modalityvascular delivery of gene therapeutics that specifically and efficiently target tissues or cells of interest-has not yet been realized.
A number of strategies have been evaluated for targeting the pulmonary vasculature, particularly those based on adenovirus serotype 5 (Ad5). The advantages of Ad5 over other systems are clear: in vivo stability, low oncogenic potential and large packaging capacity. Yet, like its counterparts, systemic targeting of Ad5 has been limited by a number of barriers in vivo, mainly sequestration of Ad5 in the liver. 4, 5 Kupffer cells (KCs) in the liver rapidly eliminate the bulk of intravenously administered Ad5 virions, [6] [7] [8] at least in part, through scavenger receptor interactions with the Ad capsid. 9 Uptake of Ad5 by KCs and other phagocytes of the reticuloendothelial system (RES) has a major role in inducing a potent innate immune response. 6, 8, [10] [11] [12] Much of the remaining virus is redirected to hepatocytes through interactions with soluble blood factors, 13 particularly factor X. 14, 15 Additional mechanisms, attributed to the unique anatomical composition of the liver, also contribute to Ad5 sequestration. 16, 17 Hence, significant effort has been aimed at ablating Ad5 liver sequestration to maximize the therapeutic potential of Ad for other clinically relevant tissues. 18 Fortunately, the plasticity of the Ad capsid proteins tolerates significant changes aimed at redirecting Ad tropism. [19] [20] [21] Several transductional-and transcriptional-targeting strategies have been evaluated to render Ad5 clinically relevant for treatment of pulmonary disease. Inefficient delivery through the airway 22 and a growing interest in targeting more complex disease processes, such as pulmonary hypertension and cancer, have encouraged the development of vascular delivery approaches. Previous vascular-targeting strategies have been achieved through the use of bispecific adapters that bind the viral capsid, masking Ad5 tropism to its natural receptor, the human coxsackie and adenovirus receptor (hCAR), and redirecting the viral tropism to receptors expressed on endothelium. 23, 24 However, these targeting strategies still result in substantial liver accumulation and hepatocyte gene transfer. 23 Although hexon mutations [25] [26] [27] [28] and transcriptional control elements 24, 29 have reduced Ad transduction and expression in hepatocytes, KC sequestration and residual gene expression within the liver remain as key barriers to clinical utility. 25, 28 Thus, systemic use of Ad5 for gene therapy of lung disease may require more efficient lung-targeting and liver-detargeting approaches.
As venous blood flow is first directed through the pulmonary vasculature, efficient targeting of cell types within the lung may preclude the need for viral modifications that ablate liver sequestration mechanisms. Leukocytes may represent an ideal target for delivery of therapeutics to the pulmonary vasculature, as the lung microvasculature represents a bottleneck that reduces leukocyte transit rate and results in their net accumulation within this tissue. 30, 31 This often-overlooked population of leukocytes, classically referred to as the marginated pool, originates from the bone marrow reserve and exceeds the circulating pool by an estimated threefold. 31 Furthermore, leukocytes directly contribute to the pathogenesis of many debilitating lung diseases, making them clinically relevant targets for therapeutic intervention of inflammatory lung disease. 32 Given the size and location of this marginated leukocyte pool, we designed a novel pulmonary-targeting approach to modulate Ad5 vector tropism to myeloid leukocytes. We previously described the development of a myeloid cell-binding Ad vector, Ad.MBP, through the incorporation of a newly identified myeloid cell-specific peptide (WTLDRGY) into a fiber knob-deleted Ad5 vector. In vitro evaluation of Ad.MBP demonstrated enhanced binding and transduction of CD11b þ myeloid cells compared to control virus (Ad.iMBP) with the same residues found in the MBP-targeting sequence, but inverted (YGRDLTW). 33 Herein, we demonstrate that this myeloid cell-binding virus results in significantly enhanced lung gene transfer to pulmonary endothelial cells (ECs) and escapes liver sequestration mechanisms in the absence of further capsid modifications. As myeloid cell-specific binding is preserved in single-cell lung suspensions and only Ad.MBP-coated myeloid cells achieved efficient EC transduction ex vivo, we believe that EC transduction is mediated by viral hand-off from myeloid cells as they traffic through the pulmonary capillary bed.
RESULTS

Biodistribution of Ad.MBP gene transfer in vivo
Previously, we have demonstrated that specific and efficient ex vivo targeting of Ad5 to myeloid leukocytes from a number of tissues, including the lung, is achieved through genetic incorporation of a 7 amino-acid peptide into knob-deleted Ad5 fibers. 33 Because circulating leukocytes are concentrated in the lung vasculature 30, 31, 34 and venous blood flow passes through the pulmonary system before the liver, we hypothesized that tail vein injection of the myeloid cell-targeted Ad.MBP vector would result in efficient gene delivery to the leukocyte-rich lung. To evaluate this, we first titrated the biodistribution of luciferase (Luc) gene expression following intravenous infusion of Ad.MBP.Luc at viral doses of 10 7 -10 10 virus particles (VP) per mouse. At all of these doses, Luc activity in the lung was significantly higher than any other tissue (Po0.001; Figure 1a ), including the liver and spleen where Ad5 gene expression is typically highest. In this regard, previous reports have utilized the ratios of lung:liver and lung:spleen gene expression as indices of lung-targeting efficiency. 24, 29, 35 As illustrated in Figure 1b , lung targeting with Ad.MBP was enhanced, compared with both liver and spleen, at all doses of virus administered. Furthermore, Ad.MBP-mediated lung gene expression was linear over a 4-log dose of Ad.MBP particles. In fact, lung gene transfer was not saturated until over 10 11 VP per mouse was administered (data not shown). Therefore, the Ad.MBP doses used for subsequent experimental end points utilized 10 10 -10 11 VP per mouse, as these doses provided the greatest differential in gene expression between lung and other tissues.
To 23, 29, 36 Ad5 gene expression is primarily localized to the liver and spleen at 24 h post-administration ( Figure 2 ). In stark contrast, Ad.MBP gene expression is localized almost exclusively to the lungs and is essentially absent from the liver and spleen ( Figure 2 ) compared with Ad5, resulting in a 205-fold increase (Po0.001) in lung gene expression and 820-fold (Po0.001) and 260-fold (Po0.001) reductions in liver and spleen gene expression, respectively. Further, we determined that targeting with the Ad.MBP vector realized 6700-fold higher transgene expression in the lung than in the liver (Po0.001). The ratio of lung:liver gene expression for non-targeted Ad5 was 0.04 (Po0.01). Thus, our targeting approach resulted in an enhancement in lung targeting of 4165 000-fold (6700Ä0.04) and a greater than 56 000-fold improvement in lung:spleen ratio, compared with that of the traditionally used Ad5-based vector.
Biodistribution of Ad.MBP virions in vivo
It has previously been shown that Ad5 virions are rapidly sequestered (within 5 min of infusion) and degraded by KCs after low dose (p10 10 VP) intravenous injection, which prevents significant detection of transgene expression at 24 h. 7, 8 Interestingly, even at a dose of 10 7 VP, we see significant lung gene expression by Ad.MBP at 24 h, demonstrating the specificity and efficiency with which Ad.MBP targets the pulmonary system ( Figure 1a ). To investigate whether the reduced liver tropism with Ad.MBP is a result from a first-pass effect through the pulmonary circulation, we evaluated the biodistribution of Ad.MBP virions immediately after intravenous injection. A 1:1 ratio (4 Â 10 10 total VP per mouse) of Ad5 and Ad.MBP virions were co-injected intravenously and the animals were killed 5 min post-injection for genomic DNA extraction from whole organs and differential detection of each virus by polymerase chain reaction. As there is a measurable size difference between the fiber genes of Ad5 and Ad.MBP, a single set of primers was designed to amplify both products as a semiquantitative measure of virion localization (the sensitivity of this assay with spiked tissue samples was determined to be 10 2 viral copies per ng of genomic DNA). Within 5 min of infusion, Ad5 virions were predominantly detected in the liver, supporting previous reports that Ad5 virions are rapidly sequestered by KCs and other liver sinusoidal cells (Figure 3a) . In stark contrast, Ad.MBP virions were detected almost exclusively in the lung at the same time point (Figure 3a ). Additional animals, co-injected with the same virus mixture and either killed 45 min later (Figure 3a ) or perfused immediately before tissue isolation (Figure 3b ), showed similar findings and indicate that Ad.MBP virions are not just transiently sequestered within the lung (Figure 3a) , and are not bound to circulating components within the lung vasculature shortly after Ad.MBP infusion (Figure 3b ). Furthermore, Ad.MBP could only be detected in the liver when the Ad5:Ad.MBP mixture was directly injected into the left ventricle, effectively bypassing the first-pass pulmonary route of circulation ( Figure 3c ). In the aggregate, these data demonstrate that Ad.MBP avoids rapid KC and liver sinusoidal VP sequestration, as well as factor X-mediated liver transduction, due to a strong first-pass effect that sequesters virions in the lung microvasculature before they reach the periphery.
The innate immune response to Ad.MBP KC uptake of systemically delivered Ad5 leads to an innate immune response characterized by the release of proinflammatory cytokines such as interleukin-6. 6, 10 Given that Ad.MBP virions have reduced sequestration in the liver, compared with Ad5 virions, we next measured interleukin-6 levels in the blood shortly after virus administration. Ad.MBP induction of serum interleukin-6 was statistically reduced 6 h after intravenous injection of virus, compared with mice injected with an equivalent dose of Ad5 (Po0.05; Supplementary Figure S1 ).
Identification of Ad.MBP transduced lung cell populations
Given the significant specificity of VP and gene transfer localization in the lung, we wanted to assess whether or not myeloid cells (particularly marginated leukocytes in the pulmonary microvasculature) were the main population transduced by the Ad.MBP virus. Mice were intravenously injected with Ad.MBP.GFP (Figures 4c and e) . However, CD31
þ ECs represented the major lung population transduced (B75%) in Ad.MBP-injected animals (Figures 4e and f) .
In addition to flow cytometric analysis, some lungs were harvested en bloc from Ad.MBP.GFP-injected mice for further analysis by immunohistochemistry. Compared with uninjected controls (Figure 5a ) and Ad5.GFP-injected mice (Figure 5b) , there is substantially more GFP staining within the lung sections from Ad.MBP.GFP-injected mice (Figures 5c and d) , corroborating our Ad.MBP binding and transduction of PECs To determine whether Ad.MBP also binds to pulmonary ECs (PECs), we decided to evaluate Ad.MBP binding to various lung cell populations. Lungs from naïve mice were collagenase treated to make a single-cell suspension and Ad.MBP was added ex vivo. Unbound virus was removed and virus binding to individual cell populations was evaluated by flow cytometry. In agreement with our previous report, 33 Ad.MBP specifically bound to CD11b þ cells in lung cell suspensions (Figure 6a ). However, Ad.MBP did not significantly bind to CD31 þ ECs (Figure 6a) . Furthermore, the majority of total Ad.MBP-bound lung cells expressed the pan-leukocyte marker CD45 (Figure 6b ) and morphologically resembled myeloid cell types (monocytes, macrophages and neutrophils) and not other cell populations such as ECs (Figure 6c ). These data suggest that Ad.MBP first binds myeloid cells and is subsequently 'handed-off' to PECs.
To assess whether Ad.MBP transduces ECs directly, two EC lines were obtained for direct in vitro testing. The first was the commercially available immortalized mouse cardiac endothelial cell (MCEC) line, and the second, a murine conditionally immortalized pulmonary microvascular endothelial cell (MiPMVEC) line. 37 Ad.MBP.GFP or Ad5.GFP control vectors were added to either MCEC or MiPMVEC and gene transfer was assessed by flow cytometry 24 h later. We have previously shown that Ad.MBP transduces CD11b þ bone marrow cells (BMCs) more efficiently than Ad5 in cell culture, 33 but the efficiency of Ad.MBP transduction of MCEC or MiPMVEC was low, even with elevated multiplicity of infections (Figures 6d and e) . Conversely, Ad5 efficiently transduced both EC lines (Figures 6d and e) . To evaluate the potential of Ad.MBP-coated myeloid cells mediating viral hand-off to ECs, we coated BMCs with either virus before co-culture with MCECs. Ad5 does not bind to BMCs from C57BL/ 6 mice. 33 Figure 6f ). In addition, no difference in MCEC transduction was noted for Ad.MBP.GFP-coated BMCs isolated from C57BL/6 mice (data not shown). These data further suggest that myeloid cell-mediated hand-off may be required for efficient PEC transduction in vivo.
DISCUSSION
The inability to achieve specific and efficient gene transfer in target cells remains as a key barrier to systemic gene delivery approaches. This lack of tissue specificity reduces the effective dose accessible to target cells and compensatory dose escalation can lead to toxicity. Here we demonstrate, for the first time, a novel genetic capsid modification strategy that retargets Ad to the lung microvasculature, which abrogates KC uptake of Ad vectors and hepatocyte transduction in the liver. These data establish an important benchmark in vector-retargeting research, and offers an important first step in validating myeloid leukocytes as a valid target for redirecting intravenously delivered Ad to the lung microvasculature. This targeting strategy may have clinical utility for gene therapy strategies aimed at treating a number of inflammatory lung diseases. 32 Historically, specific and efficient systemic targeting of Ad5 has been difficult to achieve. Retargeting strategies have focused mainly on manipulating the viral capsid proteins fiber, pIX and hexon. 19, 20 Our group previously demonstrated transductional targeting of Ad to the pulmonary vasculature using a twocomponent system in which bispecific adapters redirected Ad5 tropism to angiotensin-converting enzyme expressed on pulmonary endothelium. 23 This was the first study to report enhanced targeting of Ad5 to a specific organ after systemic delivery. However, this vector-targeting strategy failed to reduce liver accumulation (that is, KC sequestration) of Ad5 particles, 23 which is known to cause significant hepatotoxicity, 5, 6 suggesting the need for further improvement in liver-detargeting efforts.
To improve upon these studies, we conceived a novel transductional-targeting approach to localize Ad to the lung via the marginated pool of leukocytes, rather than the pulmonary microvasculature itself. These cell types were attractive targets for three reasons: (1) this large reservoir of leukocytes, referred to as the marginated pool, 34 exceeds the circulating pool of leukocytes by an estimated threefold, due to their net accumulation within the lung microvascular capillary bed; 31 (2) leukocytes directly contribute to the pathogenesis of many debilitating lung diseases; and (3) in the context of Ad vector targeting, sequestration of our retargeted Ad by circulating cell types may increase vector bioavailability, reducing the doses that may be required for efficacy. To target this cell population, we previously identified an MBP and then genetically incorporated the MBP sequence into a knob-deleted Ad fiber platform. 33 Here, we demonstrated that intravenous administration of Ad.MBP resulted in a significant 165 000-fold enhancement in the ratio of lung:liver gene expression, compared with Ad5. In comparison, the two-component adapter targeting approach, previously exploited by our group, realized a 20-fold increase in lung:liver gene expression over a non-targeted Ad5 vector. 23 Although both studies demonstrate considerable lung targeting in comparison to Ad5, adapter targeting only achieved an 83% reduction in liver transgene expression, 23 compared with the 99.9% reduction achieved with the genetically modified Ad.MBP virus described in this study. Furthermore, our results demonstrate that Ad.MBP particle localization was efficiently restricted to the lung. To our knowledge, this is the first purely transductionaltargeting approach utilizing a genetically modified Ad that results in viral escape of liver tropism (that is, KC uptake and hepatocyte transduction) in addition to efficient targeting of gene transfer to a specific organ (that is, the lung).
These data strongly support a mechanism of first-pass lung sequestration of myeloid cell-targeted Ad, as direct injection of Ad.MBP into the left ventricle (an injection site distal to the pulmonary circulation) partially restored virion sequestration in the liver. However, a substantial amount of virus particles were still localized to the lung shortly after intravenous injection proximal to the liver. This is an interesting finding, as previous studies have implicated both the fiber knob domain and hexon protein as important components for KC sequestration. 13, 38, 39 Although our data do not directly demonstrate a mitigation of KC interaction with knob-deleted Ad particles, our study suggests that KC sequestration, and the acute immune response associated with KC uptake (as measured by serum interleukin-6 levels), 5, 6, 10 can be minimized through more efficient binding of Ad to other tissues, such as the lung. Thus, liver detargeting via additional capsid modifications may not be necessary, as long as the route of injection and the efficiency of targeting or sequestration supersede viral access to the liver. 40 Finally, we propose that the marginated pool may have an integral role in the efficient and specific targeting of Ad.MBP particle binding and gene transfer to the lung. The marginated pool of neutrophils, monocytes and lymphocytes 34 represents the net accumulation of circulating leukocytes from the systemic pool that become transiently sequestered within the much smaller alveolar capillary network. 30, 31 Our data suggest that Ad.MBP virions are first sequestered on leukocytes from this marginated pool for subsequent viral 'hand-off' and gene transfer to PECs. First, lung cell binding and in vitro transduction experiments demonstrate the inability of Ad.MBP to bind or infect PECs directly. However, Ad.MBP-bound BMCs added to EC cultures resulted in enhanced EC gene transfer (while Ad5-bound BMCs were not able to improve EC gene transfer), further demonstrating that pulmonary gene transfer may be mediated via a handoff mechanism. The preferential binding of Ad.MBP to lung myeloid cell types ex vivo and the disproportionate number of Ad.MBPtransduced alveolar capillaries, compared with larger pulmonary vessels in vivo, further supports that Ad.MBP virions are first sequestered by the marginated pool for subsequent viral 'handoff' and gene transfer to PECs. Leukocytes have to change shape to navigate through the microcapillary beds. Thus, virions coating the surface of these leukocytes are in close contact with alveolar ECs, which may allow virus penton-EC integrin interactions to occur and allow virus to be efficiently handed-off and internalized directly by PECs bypassing the need for the initial attachment step of cell transduction. Indeed, similar handoff or 'hitchhiking' mechanisms have been proposed 41 and described for other viruses in vivo. 42 Since we have yet to identify the molecule(s) that interact with the 7 amino-acid MBP sequence, we cannot rule out the potential that soluble factors in vivo may contribute to MBP binding of PECs directly. Future studies will be necessary to elucidate carefully the apparent dual-tropic nature of our targeting approach and whether PEC gene transfer is truly a myeloid-dependent process in vivo. Nevertheless, our approach results in efficient and specific transduction of lung cells, indicating that this strategy should be evaluated for therapeutic delivery in the context of pulmonary disease.
The lung-targeting gains achieved through myeloid cell binding establish an important benchmark in vector-retargeting and pulmonary gene therapy. Our innovative strategy demonstrates that efficient targeting of appropriate cell types may preclude the need for additional liver-detargeting strategies, such as hexon mutations that abrogate either factor X binding [25] [26] [27] [28] or KC uptake, 38 provided the virus first binds to the appropriate cell type and is then routed through the target tissue. The studies described herein are an important first step in validating myeloid cell types as an effective intermediate for systemically targeting Ad to the pulmonary vasculature, and suggest that this strategy may have clinical significance for gene therapy of pathological conditions associated with increased numbers of inflammatory cell types, such as chronic obstructive pulmonary disease, and lung cancer. ) fetal calf serum, L-glutamine (2 mM), penicillin (100 IU ml À 1 ) and streptomycin (100 mg ml À 1 ). MiPMVEC was a generous gift from Dr Namasivayam Ambalavanan (University of Alabama at Birmingham, Birmingham, AL, USA) and its isolation is described elsewhere. 37 Briefly, the cells were derived from the H-2Kb-tsA58 transgenic mouse (Immortomouse, Charles River Laboratories, Wilmington, MA, USA). This strain expresses a temperature-sensitive mutant of the SV40 large T antigen, so that culturing MiPMVECs at 33 1C allows them to remain immortalized. However, at 37 1C the cells are no longer immortalized and can be used for experimentation. Before starting the experiments, we and others characterized the endothelial nature of these cells. 37 MiPMVECs were propagated at 33 1C as described previously, 37 and then re-seeded and grown for 72 h at 37 1C before transduction experiments. MCECs and MiPMVECs were grown on 0.1% gelatin type B (Acros Organics, Geel, Belgium) pre-treated plasticware. All cells were propagated in a humidified atmosphere of 5% CO 2 at 37 1C, unless otherwise noted.
MATERIALS AND METHODS
Animals
All mice used in this study were female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA) between the ages of 6 to 10 weeks old, unless otherwise specified. In certain instances, transgenic hCAR mice were utilized, which are a gift from Dr Sven Pettersson (Karolinska Institute, Stockholm, Sweden). These mice express a truncated form of the hCAR protein (lacking the cytoplasmic tail) from a human ubiquitin-C promoter, allowing hCAR expression in multiple tissues. 43 All methods were approved by the University of Alabama at Birmingham Institutional Animal Care and Use Committee and were performed according to their guidelines.
Viruses
The non-replicating fiber-modified Ad5-based vectors, Ad.iMBP and Ad.MBP, contain E1 substitution with enhanced green fluorescent protein (eGFP) or firefly Luc transgene cassettes (expressed from the cytomegalovirus immediate-early promoter) and fiber gene modification as described previously. 33 Briefly, the Ad5 fiber gene was modified such that the knob domain was replaced by a 95 amino-acid trimerization domain from the T4 phage fibritin protein 44 and the MBP or iMBP sequences (WTLDRGY and YGRDLTW, respectively) at the carboxyl terminus. Isogenic E1-deleted Ad5.Luc and Ad5.GFP vectors (containing cytomegalovirus immediate-early promoter/transgene cassettes) were described previously. 33 Design, propagation and purification of all viruses used herein were previously described in detail. 33 Briefly, viruses were separated by two rounds of CsCl density ultracentrifugation and dialyzed in storage buffer (10% glycerol, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 1 mM magnesium chloride, pH 7.8). VP concentration was determined with the conversion factor of 1.1 Â 10 12 VP ml À 1 per absorbance unit at 260 nm, as described previously. 45 Infectious viral titers (measured in plaque-forming units) for all unmodified Ad5 vectors were determined by tissue culture infectious dose 50 method with the 293 cell line as described in the AdEasy manufacturer's protocol (Stratagene, La Jolla, CA, USA). VP:plaque-forming unit ratios for the Ad5 viruses used in this study were p50:1.
Luc biodistribution experiments
Mice were injected by tail vein with Ad5.Luc or Ad.MBP.Luc diluted in 200 ml a-minimum essential medium. Tissues were removed 24 h postinjection and homogenized in a Mini-Beadbeater (BioSpec Products, Bartlesville, OK, USA) for the analysis of Luc biodistribution using a FB12 luminometer (Berthold Technologies, Oak Ridge, TN, USA) with Luc assay system (Promega, Madison, WI, USA). For studies involving Ad.iMBP.Luc, tissues were removed 24 h post-injection, homogenized with a TissueTearor (BioSpec Products) and analyzed with a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). Protein concentrations of tissue homogenates were determined by DC Protein Assay (Bio-Rad, Hercules, CA, USA) to normalize relative light unit values from different tissues and animals.
Virus particle localization experiments
Mice were injected (tail vein) with a cocktail of Ad5 and Ad.MBP at a 1:1 ratio (4 Â 10 10 total VP) in 200 ml Hank's balanced salt solution and killed at various time points after injection for organ removal. Some animals were perfused with phosphate-buffered saline (PBS) via the right ventricle (RV) at the time of being killed before organ collection. Other mice were first anesthetized with 50 ml pentobarbital intraperitoneally and then the virus cocktail (in 50 ml of Hank's balanced salt solution) was slowly injected directly into the left ventricle upon entry into the chest cavity. At various time points following injection, mice were killed for organ removal. For all samples, whole organs were weighed and PBS was added to each sample at a ratio of 80 ml per 25 mg tissue and then samples were homogenized in a Mini-Beadbeater. Genomic DNA was extracted from 100 ml of homogenized tissue with the DNeasy Blood and Tissue Kits (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Standards were prepared for the various tissues by spiking the virus cocktail into control (uninjected) tissues and extracting DNA in parallel with the experimental samples. An assay for PCR-based detection of viral genomes was designed as a semiquantitative measure of VP localization. As there is a measurable size difference between the fiber genes of Ad5 and Ad.MBP, a single set of primers (5 0 -TACTGGAGCCTTGGGTTTTG-3 0 and 5 0 -GCTATGTGGTGGTGGGG CTA-3 0 ) was designed such that both products (1127 and 1004 bp, respectively) would be amplified in a single reaction. 
Ad.MBP.GFP in vivo experiments
Mice were injected (tail vein) with Ad5.GFP or Ad.MBP.GFP at 2.5 Â 10 10 VP for both flow cytometric and immunohistochemical analysis. For the former, lungs were removed 24 h post-injection and a single-cell suspension was obtained from Liberase digestion as described above. Cells were washed in PBS supplemented with 2% fetal calf serum (fluorescence-activated cell sorting (FACS) buffer), and counted and stained for flow cytometry. For the latter, mice were anesthetized 24 h post-injection and then perfused via the right ventricle with 10 ml PBS supplemented with heparin (1 U ml À 1 ), followed by 5 ml 10% neutralbuffered formalin. Lungs were removed en bloc, inflated with 1-2 ml 10% neutral-buffered formalin, and then tied off and left at room temperature overnight submerged in 10% neutral-buffered formalin. The next day, lungs were switched to 70% ethanol before trimming and processing for paraffin embedding and sectioning below.
Lung immunohistochemistry
Paraffin sections (5 mm) were melted on slides at 60 1C for 1 h, deparaffinized in xylene and then rehydrated in ethanol (100, 95, 85 and 70%). Slides were washed in PBS before performing antigen retrieval by boiling in Citric Acid Based Antigen Unmasking Solution (Vector Labs, Burlingame, CA, USA) for 12 min in an 800 W microwave. Slides were washed in PBS, incubated at room temperature in blocking buffer (PBS supplemented with 5% goat serum and 1% bovine serum), followed by incubation with primary antibodies in fresh blocking buffer overnight at 4 1C in a humidity chamber. Slides were washed in PBS, incubated at room temperature in blocking buffer, and then with secondary antibodies for 1 h at room temperature in a humidity chamber. Slides were rinsed in PBS and mounted in VECTASHIELD HardSet Mounting Medium with DAPI (Vector Labs). Image acquisition was performed on a Leica DM6000B epifluorescence microscope (Leica Micorsystems, Wetzlar, Germany) with SimplePCI Imaging software (Compix Media Inc., Irvine, CA, USA). The following
